{"id":"W4379797691","doi":"10.1136/annrheumdis-2023-eular.3412","title":"AB1105 LONG-TERM SAFETY OF IXEKIZUMAB TREATMENT IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: A POST-HOC ANALYSIS OF END-OF-STUDY PROGRAM DATA RELATING TO MAJOR ADVERSE CARDIOVASCULAR EVENTS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Memorial University of Newfoundland","funders":"Agencia Estatal de Investigación; Sanofi Genzyme; Bausch Health; Sanofi; Kyowa Hakko Kirin; Celltrion; Galderma; XBiotech; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Castle Biosciences; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Helsinn; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Helsinn Therapeutics; Amgen","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Psoriasis; Post-hoc analysis; Arthritis; Adverse effect; Dermatology; Internal medicine; Secukinumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005118183,0.0007742986,0.002488528,0.0003140461,0.0003440093,0.001231687,0.0005852995,0.0007466709,0.001893535],"category_scores_gemma":[0.002840453,0.0003775341,0.003735078,0.0003439783,0.0005118279,0.000946075,0.0004731119,0.001840812,0.0002500372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000513231,"about_ca_system_score_gemma":0.0009091633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009113672,"about_ca_topic_score_gemma":0.001424939,"domain_scores_codex":[0.9973801,0.001422794,0.0001784462,0.0004045223,0.0002208913,0.0003932506],"domain_scores_gemma":[0.9974936,0.001197733,0.0004563682,0.000294504,0.0001893358,0.0003684555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8831419,0.002188831,0.07648254,0.0002886314,0.01036069,0.000156757,0.00009469587,0.001310134,0.004578379,0.00008729543,0.0005483904,0.02076176],"study_design_scores_gemma":[0.1027132,0.2459771,0.6199074,0.00009916922,0.0163047,0.0004636084,0.0002912503,0.007294989,0.004524305,0.0003087211,0.00201032,0.0001052223],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981045,0.0007581589,0.0001814549,0.00005403195,0.00003982456,0.00005998935,0.0003921187,0.00001152979,0.0003982967],"genre_scores_gemma":[0.9986246,0.0001481657,0.0001140268,0.00007054514,0.00005153082,0.00004323493,0.000564108,0.000004018975,0.000379852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005118183,"threshold_uncertainty_score":0.02706784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02885859622965414,"score_gpt":0.2903887033458657,"score_spread":0.2615301071162116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}